SF3B1 K666N

CI-VAR-00002167Explore in graph →NP_036565.2:p.Lys666AsnNM_012433.3:c.1998G>TClinVar 219098 CIViC 114 rs377023736

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
SF3B1 K666N	Spliceostatin A	Predictive	D	Supports Sensitivity Response	2	accepted	EID1418 Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 m… (full text at CIViC) PMID 25424858 · Maguire et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
219098	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Myelodysplastic syndrome progressed to acute myeloid leukemia; Myelodysplastic syndrome	somatic	2	Oct 10, 2021	clinvar